Literature DB >> 21669578

Borderline resectable pancreatic tumors: is there a need for further refinement of this stage?

Shailesh V Shrikhande1, Supreeta Arya, Savio George Barreto, Sachin Ingle, Melroy A D'Souza, Rohini Hawaldar, Parul J Shukla.   

Abstract

BACKGROUND: The ideal treatment of patients with "borderline resectable pancreatic tumors (BRTs)" needs to be established. Current protocols advise neoadjuvant chemo(radio)therapy, although some patients may appear to have BRT on preoperative imaging and a complete resection may be achieved without the need for vascular resection. The aim of the present study was to identify specific findings on preoperative imaging that could help predict in which patients with BRT a complete resection, with or without vascular resection (VR), could be achieved.
METHODS: Twelve patients with BRTs were identified. Tumor location, maximum degree of circumferential contact (CC), length of contact of the tumor with major vessels (LC), and luminal narrowing of vessels at the point of contact with the tumor (venous deformity, VD) were graded on preoperatively acquired multidetector computed tomography (MDCT) images and then compared with the intraoperative findings and need for VR.
RESULTS: A complete resection (R0) was achieved in 10 patients with 2 having microscopic positive margins (R1) on histopathology at the uncinate margin. Four of the 10 patients required VR (40%). In 3 of the 4 patients whose tumors required VRs, CC was ≥grade III and VD was grade 2. LC did not influence the need for VR.
CONCLUSIONS: It is possible to achieve a complete resection at the first instance in patients found to have BRTs on preoperative imaging. Preoperative MDCT-based grading systems and our proposed criteria may help identify such patients, thus avoiding any delay in curative resections in such patients.

Entities:  

Mesh:

Year:  2011        PMID: 21669578     DOI: 10.1016/s1499-3872(11)60053-2

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  5 in total

1.  Surgery for Pancreatic and Periampullary Carcinoma.

Authors:  Abhishek Mitra; Ashwin D'Souza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2015-10-10       Impact factor: 0.656

Review 2.  Advances in chemotherapy for pancreatic cancer.

Authors:  Bhawna Sirohi; Ashish Singh; Shaheenah Dawood; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2015-01-13

3.  Surgery for pancreatic carcinoma: state of the art.

Authors:  Shailesh V Shrikhande; Savio George Barreto
Journal:  Indian J Surg       Date:  2011-11-24       Impact factor: 0.656

Review 4.  Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.

Authors:  Shailesh V Shrikhande; Savio George Barreto; Mahesh Goel; Supreeta Arya
Journal:  HPB (Oxford)       Date:  2012-06-14       Impact factor: 3.647

5.  Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Ho Kyoung Hwang; Woo Jung Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2013-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.